Publicaciones (58) Publicaciones de Marta Santisteban Eslava

2024

  1. Dendritic Cells in Cancer Immunology and Immunotherapy

    Cancers, Vol. 16, Núm. 5

  2. Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line

    Clinical and Translational Oncology

2023

  1. Futuro y líneas de investigación clínica del cáncer de mama triple negativo avanzado

    Revisiones en Cancer, Vol. 37, Núm. 1, pp. 17-29

  2. Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies

    Biomedicines, Vol. 11, Núm. 2

2022

  1. A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

    Cancers, Vol. 14, Núm. 12

  2. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer

    Frontiers in Immunology, Vol. 13

  3. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268

  4. Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

    BMC Cancer, Vol. 22, Núm. 1

  5. Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer

    Cancer Discovery, Vol. 12, Núm. 5, pp. 1356-1377

2021

  1. Body shape trajectories and risk of breast cancer: Results from the SUN ('Seguimiento Universidad de Navarra') Project

    Public Health Nutrition, Vol. 24, Núm. 3, pp. 467-475

  2. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

    European Journal of Cancer, Vol. 152, pp. 68-77

  3. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

    Annals of Oncology, Vol. 32, Núm. 10, pp. 1245-1255

  4. Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis

    Therapeutic Advances in Medical Oncology, Vol. 13

  5. Leisure-time physical activity, sedentary behavior, and risk of breast cancer: Results from the SUN (‘Seguimiento Universidad De Navarra’) project

    Preventive Medicine, Vol. 148

2020

  1. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428

  2. Binge drinking and risk of breast cancer: Results from the SUN (‘Seguimiento universidad de Navarra’) project

    Nutrients, Vol. 12, Núm. 3

  3. Complete cytoreductive surgery, the key factor for survival in advanced ovarian cancer. Experience of an intermediate volume hospital

    European Journal of Gynaecological Oncology, Vol. 41, Núm. 6, pp. 906-912

  4. GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain

    Oncologist, Vol. 25, Núm. 9, pp. e1339-e1345

  5. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Breast, Vol. 54, pp. 286-292

  6. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)

    Breast Cancer Research and Treatment, Vol. 184, Núm. 2, pp. 469-479